Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China

Abstract EN

Purpose.

To evaluate the efficacy of intravitreal melphalan for vitreous seeds from retinoblastoma in Chinese patients.

Methods.

This is a retrospective review of 17 consecutive Chinese patients (19 eyes) with viable vitreous seeds from retinoblastoma.

The patients received multiple intravitreal injections of 20 ug melphalan.

Results.

The International Classification of Retinoblastoma groups were B in 1 eye, C in 5 eyes, D in 11 eyes, and E in 2 eyes.

On average, 6 injections (range: 1–15) were given to each eye at the interval of 2–4 weeks.

Successful control of vitreous seeds was achieved in 16 of 19 eyes (84.21%).

Globe retention was achieved in 73.68% (14/19) eyes.

The patients were followed up for 27 months on average (median: 26; range: 17–42 months).

There is a significant difference in response to intravitreal melphalan for cloud, spheres, and dust seeds with a median number of injections of 9, 6, and 3, respectively (P=0.003).

Complications related to intravitreal melphalan included vitreous hemorrhage, cataract, salt-and-pepper retinopathy, and pupil posterior synechia.

There was no case of epibulbar extension or systemic metastasis within the period of follow-up.

Conclusion.

Intravitreal melphalan achieved a high local control rate for vitreous seeds without extraocular extension and with acceptable toxicity in Chinese retinoblastoma patients.